ChemoCentryx Announces Upcoming Conference Abstracts Focused on TAVNEOS (avacopan) and the Burden of Systemic Glucocorticoid Use in ANCA-Associated Vasculitis
SAN CARLOS, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced upcoming presentations at three key medical conferences that will highlight findings from
the pivotal Phase III ADVOCATE trial that supported the approval of TAVNEOS (avacopan), an orally administered selective complement 5a receptor (C5aR) inhibitor, and research into the burden of
glucocorticoid use in ANCA-associated vasculitis.
ATS 2022 (American Thoracic Society), May 15-17, San Francisco
Insights from the ADVOCATE Study: Respiratory Tract Involvement in Patients with ANCA-Associated Vasculitis in a Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Avacopan
Tuesday, May 17 at 3:15 PM PT
Room 11-12, South Building, Exhibition Level, Moscone Center
Session: Mini Symposium: Clinical Trials in Chronic Lung Disease
ISPOR 2022 (International Society for Pharmacoeconomics and Outcomes Research), May 15-18, Washington, DC/Virtual
The Burden of Systemic Glucocorticoid (GC) Use in Anti-Neutrophilic Cytoplasmic Autoantibody (ANCA)-Associated Vasculitis Patients
Tuesday, May 17 from 5:30 - 6:30 PM ET
Prince George Exhibit Hall, Area A
59th ERA Conference (European Renal Association), May 19-22, Paris, France/Virtual
Incidence of Infections in the Avacopan Group Versus Prednisone Group in ANCA-Associated Vasculitis, Results from the Phase 3 ADVOCATE Study
Friday, May 20 from 5:00 PM – 6:30 PM CEST
Session: New insights from clinical trials in ANCA-associated vasculitis
TAVNEOS (avacopan) is indicated as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] and microscopic polyangiitis [MPA]) in combination with standard therapy including glucocorticoids. TAVNEOS does not eliminate glucocorticoid use.
IMPORTANT SAFETY INFORMATION
Serious hypersensitivity to avacopan or to any of the excipients
WARNINGS AND PRECAUTIONS
Hepatotoxicity: Serious cases of hepatic injury have been observed in patients taking TAVNEOS, including life-threatening events. Obtain liver test panel before initiating TAVNEOS, every 4 weeks after start of therapy for six months and as clinically indicated thereafter. Monitor patients closely for hepatic adverse reactions and consider pausing or discontinuing treatment as clinically indicated (refer to section 5.1 of the Prescribing Information). TAVNEOS is not recommended for patients with active, untreated and/or uncontrolled chronic liver disease (e.g., chronic active hepatitis B, untreated hepatitis C, uncontrolled autoimmune hepatitis) and cirrhosis. Consider the risk and benefit before administering this drug to a patient with liver disease.